Cabot Wealth Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-2,836
Closed -$203K 143
2016
Q4
$203K Sell
2,836
-6,627
-70% -$493K 0.05% 145
2016
Q3
$749K Sell
9,463
-45,038
-83% -$3.66M 0.19% 97
2016
Q2
$4.55M Buy
54,501
+376
+0.7% +$33.4K 1.2% 29
2016
Q1
$4.97M Buy
54,125
+142
+0.3% +$12.8K 1.38% 26
2015
Q4
$5.46M Buy
53,983
+28,353
+111% +$2.95M 1.4% 19
2015
Q3
$2.52M Buy
+25,630
New +$2.85M 0.7% 59

Other funds holding GILD

Cabot Wealth Management's GILD Position: Q1 2017 in Review

Cabot Wealth Management sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 2,836 shares — an estimated $203K sold.

Cabot Wealth Management first reported a position in GILD in Q3 2015 and held it in 6 quarters. The position peaked at $5.46M in Q4 2015. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

  • Cabot Wealth Management reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
  • Cabot Wealth Management sold 2,836 Gilead Sciences shares in Q1 2017, an estimated $203K.
  • Cabot Wealth Management first reported a position in Gilead Sciences in Q3 2015 and held it in 6 quarters.
  • Cabot Wealth Management's Gilead Sciences position peaked at $5.46M in Q4 2015.
  • 1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Cabot Wealth Management's 13F filing for Q1 2017, filed 9 May 2017.